AVALO THERAPEUTICS, INC. Proceeds from License Fees Received
AVALO THERAPEUTICS, INC. (AVTX) reported Proceeds from License Fees Received of $19.50 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-29.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromLicenseFeesReceived · last filed 2023-03-29
- AVALO THERAPEUTICS, INC. proceeds from license fees received for fiscal 2022 was $19.50M.
| Period end | Proceeds from License Fees Received | Proceeds from License Fees Received 1 month | Proceeds from License Fees Received 12 month |
|---|---|---|---|
| 2022-12-31 | $19.50M 10-K · filed 2023-03-29 | ||
| 2022-07-31 | $14.50M 10-Q · filed 2022-11-07 | ||
| 2017-08-14 | $25.00M 10-Q · filed 2017-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |